30-year cardiovascular disease in type 1 diabetes: risk and risk factors differ by long-term patterns of glycemic control
Miller RG, Orchard TJ, Costacou T
Diabetes Care. 2022;45(1):142-150.
Leggi
Breaking news
Do gene–environment interactions have implications for the precision prevention of type 2 diabetes?
Sørensen TIA, Metz S, Kilpeläinen TO
Diabetologia. Pub. online 7 Jan 2022.
Leggi
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt B, Filippatos G, Agarwal R, et al.
N Engl J Med. 2021;385(24):2252-2263.
Leggi
Islet autoantibody type-specific titer thresholds improve stratification of risk of progression to type 1 diabetes in children
Kenney NG, Stavropoulos H, Anand V, et al.
Diabetes Care. 2022;45(1):160-168.
Leggi
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
Shi Q, Wang Y, Hao Q, et al.
Lancet. 2021;S0140-6736(21)01640-8.
Leggi
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
Rossing P, Inzucchi SE, Vart P, et al.
Lancet Diabetes Endocrinol. 2022;10(1):24-34.
Leggi
The changing character of diabetes complications
Bellary S
Lancet Diabetes Endocrinol. 2022;10(1):5-6.
Leggi
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
Verma S, Dhingra NK, Butler J, et al.
Lancet Diabetes Endocrinol. 2022;10(1):35-45.
Leggi
Glycaemic management in diabetes: old and new approaches
Ceriello A, Prattichizzo F, Phillip M, et al.
Lancet Diabetes Endocrinol. 2021;S2213-8587(21)00245-X.
Leggi
Continuous glucose monitoring systems for monitoring cystic fibrosis‐related diabetes
Toner A, McCloy A, Dyce P
Cochrane Database Syst Rev. 2021;11(11):CD013755.
Leggi